Original Research Paper

Synthetic anti-angiogenic genomic therapeutics for treatment of neovascular age-related macular degeneration

Jing Wang, Xiang Shi, Qiyu Bo, Hong Wang, Fang Wei, Jun Liu, Hao Wang, Liuwei Zhang, Yan Qi, Zhen Li, Qixian Chen, Xiaodong Sun

A Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
B Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
C Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
D National Clinical Research Center for Eye Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
E Ningbo Hygeia Medical Technology Co., Ltd., Ningbo 315201, China
F School of Bioengineering, Dalian University of Technology, Dalian 116024, China
G College of Pharmacy, Dalian Medical University, Dalian 116044, China

ABSTRACT

In light of the intriguing potential of anti-angiogenic approach in suppressing choroidal neovascularization, we attempted to elaborate synthetic gene delivery systems encapsulating anti-angiogenic plasmid DNA as alternatives of clinical antibody-based therapeutics. Herein, block copolymer of cyclic Arg-Gly-Asp-poly(ethylene glycol)-polylysine-thiol) [RGD-PEG-PLys(thiol)] with multifunctional components was tailored in manufacture of core-shell DNA delivery nanoparticles. Note that the polycationic PLys segments were electrostatically complexed with anionic plasmid DNA into nanoscaled core, and the tethered biocompatible PEG segments presented as the spatial shell (minimizing non-specific reactions in biological milieu). Furthermore, the aforementioned self-assembly was introduced with redox-responsive disulfide crosslinking due to the thiol coupling. Hence, reversible stabilities, namely stable in extracellular milieu but susceptible to disassemble for liberation of the DNA payloads in intracellular reducing microenvironment, were verified to facilitate transcellular gene transportation. In addition, RGD was installed onto the surface of the proposed self-assemblies with aim of targeted accumulation and internalization into angiogenic endothelial cells given that RGD receptors were specifically overexpressed on their cytomembrane surface. The proposed anti-angiogenic...
DNA therapeutics were validated to exert efficient expression of anti-angiogenic proteins in endothelial cells and elicit potent inhibition of ocular neovascularization post intravitreous administration. Hence, the present study approved the potential of gene therapy in treatment of choroidal neovascularization. In light of sustainable gene expression properties of DNA therapeutics, our proposed synthetic gene delivery system inspired prosperous potentials in long-term treatment of choroidal neovascularization, which should be emphasized to develop further towards clinical translations.

© 2021 Shenyang Pharmaceutical University. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

1. Introduction

Indulgence in electronic displays, owing to their high-energy visible light and ultraviolet, has prompted a rapidly growing population of choroidal neovascularization (CNV), which has been acknowledged to be a major cause of blindness across the world. In reference to the recent statistics, CNV comprises an estimated 2.5% of people aged over 40 years [1–3]. Note that wet age-related macular degeneration (wAMD) was characterized by CNV, which provokes progressive leakage of blood and fluid, eventually leading to vision loss [4–6]. In principle, CNV is stimulated by vascular endothelial growth factor (VEGF), diffusible cytokines that prompt angiogenesis and vascular permeability [7,8]. Pertaining to the clinical therapeutic regime, intravitreal administration of VEGF antagonists (e.g. ranibizumab or bevacizumab) that specifically bind to the VEGF, have been verified to be a valid approach in suppressing CNV progression of wAMD and improving visual acuity [9–14]. Nonetheless, the aforementioned antibody-based therapeutics are required to be repeatedly administered at 4–8 weeks interval, which not only conflicts the patient compliance but also increases the risks of ocular inflammation, retinal injury and endophthalmitis [15,16]. To this drawback, gene therapy as alternative to antibody-based therapeutics is desirable in light of long-term protein expression of the encoded therapeutic gene in the affected cells [17,18]. For instance, genomic therapeutics recently developed by our laboratory have demonstrated intriguingly consistent gene expression in cell spheroids over 90 days, and the levels of the expressed proteins were recorded to be appreciably constant [19]. Hence, this tempting constant gene expression profile is postulated to not only allow reduced dosage frequencies (thus improved patient compliance) but also contribute to improved therapeutic outcomes in respect to the constant retention of high level of therapeutic proteins in the pathologic sites.

However, to accomplish gene therapy, appropriate delivery systems are imperative to transport the inherently biologically fragile DNA to the cell interior (cell nucleus) for efficient gene expression since the supramolecular DNA owing to its large scale (micrometer) and intrinsic negative-charge forbids its diffusion across the lipophilic and negatively charged cytomembranes, not to mention the other biological barriers hindering the successful intracellular gene transportation [20,21]. It should be noted for viral vectors, despite their tempting transfection efficiencies, whose fatal concerns (e.g. severe immunogenicity, limited gene-loading capacity and difficulties in industrial scale-up) motivate us to seek an alternative approach in manufacture of delivery vehicles for intracellular gene transportation [22,23]. To the essential prerequisites for gene delivery, we intended to exploit materials-based molecular design in manufacture of non-viral synthetic gene delivery systems to accomplish gene therapy.

In the present research, the negatively charged plasmid DNA was schemed to electrostatically complex with cationic block copolymers of poly(ethylene glycol)-polylysine (PEG-Plys). Consequently, the DNA condenses initialized by electrostatic complexation with the cationic Plys segments as the internal core, was postulated to be surrounded by the hydrophilic and biocompatible PEG shell. With the aim of adequate colloidal stability in the physiological environment, thiol groups were introduced into the side chains of Plys with the intention of crosslinking of the internal pdNA/Plys core by means of disulfide linkage between the thiol arms. Notably, the disulfide linkage was fairly stable in the extracellular milieu (relative oxidizing environments), thereby affording substantial stability to withstand the potential structural dissociation in the bloodstream or extracellular milieu. On the contrary, the disulfide bond is susceptible to cleavage in the intracellular compartments. Note that the intracellular milieu is characterized to be remarkably reducing compartments, intracellular structural disassembly from the proposed self-assemblies could be readily anticipated in subsequent to disulfide cleavage, which consequently facilitates the pDNA release from the aforementioned DNA self-assemblies for smooth gene expression machinery. On the other hand, targeting moieties of cyclic Arg-Gly-Asp (RGD) peptide were also installed onto the surface of the PEGylated self-assemblies. In view the specific affinities of RGD peptide to the angiogenic vasculatures (the receptors of RGD, including αVβ3 and αVβ6 integrins, are overexpressed on the angiogenic endothelial cells), hence preferential accumulation and thus efficient protein expression of therapeutic proteins (anti-VEGF) in CNV could be envisioned in the treatment of wAMD.

2. Materials and methods

2.1. Materials

α-Methoxy-ω-amino-PEG (Mw 12,000) and acetal-PEG-NH₂ (Mw 12,000) was purchased from SinoPEG Co. (Xiamen, China). N-Trifluoroacetyl-L-lysine N-carboxyanhydride [lys(TFA)-NCA] was purchased from Hubei Jusheng Co. (Wuhan, China). Dithiothreitol (DTT), diethylenetriamine (DET), N,N-
dimethylformamide (DMF), dichloromethane, benzene, and trifluoroacetic acid were purchased from Wako Pure Chemical Industries, Ltd. N-succinimidyl-3-(2-pyridyldithiol)propionate (SPDP) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Fetal bovine serum (FBS) was purchased from Dainippon Sumitomo Parma Co., Ltd. (Osaka, Japan). Cell culture lysis buffer and luciferase Assay System Kit was purchased from Promega Co. (Madison, WI). Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Sigma–Aldrich (St. Louis, MO). In pertinent to the cellular uptake and intracellular distribution assay, pDNA was labeled with Cy5 using a Label IT Nucleic Acid Labeling Kit from Mirus Bio Corporation (Madison, WI) according to the manufacturer’s protocol. For aqueous phase SEC, LC-2000 system (JASCO, Tokyo, Japan) equipped with Superdex200 10/300 GL (GE Healthcare, Tokyo, Japan) and a UV detector was used for characterizations. All animal experimental procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals as stated by the guidelines of Shanghai General Hospital (Shanghai Jiao Tong University School of Medicine).

2.2. Polymer synthesis

Block copolymer of PEG-PLys(thiol) and RGD-PEG-PLys(thiol) was synthesized based on ring opening polymerization. In brief, amine-functionalized Meo-PEG-NH₂ was employed as macroinitiator for polymerization of monomers of Lys(TFA)-NCA for block copolymeric PEG-PLys(TFA). The protective TFA groups was removed by hydrolysis reaction in NaOH. Furthermore, thiol groups were introduced into the side chain of the synthetic PLys segment in block copolymeric PEG-PLys based on its reaction with SPDP. The yielded PEG-PLys(SPDP) was transferred under treatment of DTT to obtain PEG-PLys(thiol). On the other hand, acetal-PEG-NH₂ was employed for synthesis of acetal-PEG-PLys(thiol) by following the similar synthetic route, which was transferred for acidic treatment to yield aldehyde-PEG-PLys(thiol). Cysteine-functionalized cyclic RGD was attempted for reaction with aldehyde group of aldehyde-PEG-PLys(thiol) to obtain the ultimate RGD-PEG-PLys(thiol). The detailed synthetic procedures were described in Supporting Information.

2.3. Dynamic light scattering (DLS)

The hydrodynamic diameters of the formulated pDNA delivery systems were measured by DLS (Zetasizer nanosseries, Malvern Instruments Ltd., Worcestershire, UK). All DLS measurements were conducted independently for at least three times at 25 °C. Note that the rate of decay in the photon correlation function was analyzed by referring to a cumulant method. Accordingly, the yielded hydrodynamic diameters were concluded based on the Stokes-Einstein equation.

2.4. Cellular uptake

Human umbilical vein endothelial cells (HUVECs) were seeded onto 24-well culture plates (20 000 cells/well) in 400 μl cell culture medium containing 10% FBS and 1% antibiotics (penicillin and streptomycin) and incubated in a humidified atmosphere supplemented with 5% CO₂ at 37°C. After 24 h incubation, the medium was replaced with fresh medium. The cells were treated by addition of PEG-PLys/pDNA, PEG-PLys(thiol)/pDNA and RGD-PEG-PLys(thiol)/pDNA (1 μg of Cy5-labeled pDNA/well) and followed by another 24 h incubation. The medium was discarded, and the cells were washed three times with ice-cold PBS to remove extracellular fluorescence. Furthermore, the cells were subjected to trypsin-EDTA treatment, and the trypsinized cells were harvested and resuspended in 1 ml ice-cold PBS. The cell suspension was filtered through a nylon mesh and transferred for analysis by a BD™ LSR II flow cytometer equipped with FACS-Diva™ software (BD Biosciences, Franklin Lakes, NJ) to quantify the intracellular pDNA quantity. Note that the cellular uptake efficiencies were expressed as the mean fluorescence intensities from Cy5-pDNA based on three independent samples (n = 3).

2.5. Gene expression efficiency

HUVECs were seeded onto 24-well culture plates (20 000 cells/well) in 400 μl cell culture medium containing 10% FBS and 1% antibiotics (penicillin and streptomycin) and incubated in a humidified atmosphere supplemented with 5% CO₂ at 37°C. At 24 h post incubation, gene delivery systems containing the reporter pDNA or CAG-Luc were added to each well for 48 h incubation. Note that fresh medium was replaced at 24 h interval. At 48 h post transfection, the cells were washed three times with 400 μl ice-cold PBS and lysed in 150 μl cell lysis buffer at 37°C for 10 min. Furthermore, 20 μl of the cell lysate was transferred into a 96-well luminometry plate, followed by addition of 100 μl of Luciferase Assay Reagent (Promega, Madison, WI), and allowed for 15 min reaction. The expressed Luc protein was quantified for 10s recording of the photoluminescence intensities by Mithras LB 940 (Berthold Technologies, Bad Wildbad, Germany). Meanwhile, the quantities of the total protein in the cell lysate was quantified according to the classical Micro BCA™ Protein Assay Kit (Pierce, Rockford, IL). The obtained Luc activities was normalized against the corresponding quantities of the total protein in the cell lysates. Herein, the gene expression levels were expressed as relative light units (RLU) per mg of protein (RLU/mg protein) (n = 4).

2.6. Animals

C57BL/6 mice (approximate 7 weeks, 20 g) were used in anti-CNV study. Note that all the animal experiments were conducted strictly according to the guidelines of the ARVO statement for the Use of Animals in Ophthalamic and Vision Research. The experimental protocols were approved by Institutional Animal Care and Use Committee of Shanghai Jiao Tong University (Shanghai, China). The mice were housed and subjected to containment in the animal care services facility with 12 h light/dark cycle and constant access to nourishments.

2.7. Laser-induced CNV

CNV was established according to our previously reported protocol. In brief, pupil dilatation was performed
with tropicamide (Santen, Osaka, Japan), followed by anesthetization based on intraperitoneal injection of 1% pentobarbital sodium (0.1 ml/10 g body weight, Guge Biotech, Wuhan, China) into C57BL/6 mice. To proceed photoagulation,loxacin eye ointment (Xing Qi Pharmaceutical Companies, Shenyang, China) was placed on top of corneal, and four laser spots were located at the vicinities of the optic nerve head with an argon laser (110 mW, 100 ms, 50 μm, OcuLight Infrared Laser System 810 nm, Iridex Corp., Mountain View, CA, USA). Appearance of a gray bubble indicative of the rupture of Bruch’s membrane were included. If retinal bleeding occurred, the animal was eliminated. Eyes were enucleated at different time points.

2.8. Intravitreal injection

Synthetic gene delivery systems containing sFlt-1 were intravitreal administered into the vitreous cavity using fine, 32-G needles and 10 μl syringes (cat. No 80,330; both form Hamilton, Reno, NV). Note that the injection process was carefully conducted with the aids of microscope through the flattened cornea (covered with ointment), and the tip of the needle is required to penetrate the sclera, choroid, and retina to reach the vitreous cavity. An approximate volume of 2 μl per injection was applied to each eye.

2.9. Fluorescence angiography

FA imaging was conducted on day 7 post photoagulation to assess the severity of CNV leakage. Prior to FA imaging, mice were subjected to sequential intraperitoneal dosage of 1% sodium pentobarbital (Guge Biotech, Wuhan, China) for anesthetization at 5 μl/g body weight and 10% fluorescein sodium (0.5 ml, Fluoresceite, Alcon, Tokyo, Japan) for bio-imaging. Fundus angiogram photos were captured at the middle stage (2–3 min post injection of fluorescein sodium) using a digital fundus camera (Heidelberg Retina Angiograph, Vista, CA). Furthermore, the relative fluorescence intensity of each CNV lesion was quantified with the aids of ImageJ platform (National Institutes of Health, Bethesda, MD). The average intensity of each CNV lesion with leakage was calculated according to our previously reported protocol (Burgess et al., 2010). In brief, an outline was drawn to encompass each CNV area, and mean fluorescence was measured, along with three adjacent background readings. The total corrected CNV fluorescence (TCCF)=integrated density – (area of selected area×mean fluorescence of background readings), was calculated. This TCCF was equalized against the mean TCCF of retina vessels, with results presented as fold increase over interphase levels. We defined the intensity of retinal vessels as one and the avascular area as zero and the signal intensity for each pixel was represented from zero (darkest) to one (brightest).

2.10. Perfusion fixation

Immunofluorescence procedures require perfusion fixation to stabilize the proteins or peptides in the choroid in order to allow for subsequent antibody binding to the antigenic site on those proteins or peptides. At end points of Day 7 after laser and sFlt-1 treatment, mice were perfused transcardially with cold 4% paraformaldehyde using a previously described protocol with minor modifications (Gerfen, 2003). In brief, mice were administered with an over dose (0.2 ml) of 1% sodium pentobarbital and monitored until the point when the animal fails to respond to pinching of the foot. Incisions in the abdomen and diaphragm were made to expose the heart and perfusion needle was placed into ascending aorta. Cold 4% paraformaldehyde was poured into left ventricle of mouse through a peristaltic perfusion pump (Cole-Parmer Masterflex, NY). Twisting of muscles suggests that the perfusion is proceeding properly. After the effluent runs clear, pump was stopped, eyes and spleens were harvested, post-fixed for 2 h and then placed in PBS to make choroidal flatmounts or put into 30% sucrose solutions to make frozen sections.

2.11. Choroidal flatmount and immunofluorescence staining

Choroidal flatmounts were performed under an operating microscope (Olympus, Tokyo, Japan) subsequent to perfusion fixation and post-fixation. In brief, the cornea, lens and vitreous were removed from the harvested eye. The retina was carefully dissected from the choroid. Furthermore, six radial incisions were applied to the remaining RPE-choroid cup for flattened choroid, which is immediately transferred for immunostaining treatment. Prior to immunostaining, the RPE-choroid complexes were blocked in 5% goat serum albumin (containing 0.3% Triton X-100) for 1 h at room temperature, followed by incubation with FITC-labeled isoclectin-B4 (IB4) (FL-1201, Vector Laboratories, Burlingame, CA) at 4 °C. After overnight reaction, the RPE-choroid complexes were rinsed and transferred for incubation with Alexa Fluor 488-labelled secondary antibodies (SA00003-11, Proteintech, Chicago, MI) for 1 h at room temperature. Eventually, fluorescence images were conducted under a fluorescence microscope (Olympus, Tokyo, Japan) or a confocal laser scanning microscope (CLSM) (Leica TCS SP8, Leica TCS NT, Wetzlar, Germany).

2.12. Statistical analysis

The P values were determined based on the Student’s t-test using a two-tailed distribution and two-sample unequal variance with the T. Test function of Microsoft Excel. The P values less than 0.05 were considered as statistically significant.

3. Results and discussion

3.1. Synthesis of block copolymeric RGD-PEG-Plys(thiol) and chemical characterizations

The block copolymer of RGD-PEG-Plys(thiol) was synthesized according to Fig. 1. In brief, acetal-PEG-NH₂ was employed as the macro-initiator for ring-opening polymerization of the monomers of Lys(TFA)-NCA for production of acetal-PEG-Plys(TFA). Furthermore, the protecting TFA residues in the units of Pllys(TFA) segment were removed under
treatment in NaOH (0.1 N) to yield cationic block copolymer of acetal-PEG-PLys. Furthermore, the amino groups of lysine in acetal-PEG-PLys were used for conjugation of SPDP, followed by DTT treatment to yield the thiol groups. Ultimately, acetal-PEG-PLys(thiol) was incubated in acidic condition for transformation of the terminus acetal groups into aldehyde groups, which was schemed to react with cysteine groups from RGD to yield the ultimate block copolymer of RGD-PEG-PLys(thiol). The resulting copolymeric RGD-PEG-PLys(thiol), as well as the control copolymers of PEG-PLys, were characterized by both 1H NMR and C-NMR measurements (Figs. S1–S5). As shown in Fig. S5, the polymerization degree of PLys segment was determined to be approximate 60.4, and the percentage of thiol substitution was estimated to be approximate 14.6% in relative to the total lysine units. Moreover, successful conjugation of cyclic RGD to the block copolymer was verified due to the evident peaks at 7.2–7.3 ppm, assignable to the protons from the phenyl groups of RGD, and the conjugation efficiency was estimated to exceed 97.2% per block copolymer. GPC measurement for the ultimate RGD-PEG-PLys(thiol) copolymer verified appreciable unimodal molecular weight distribution (Fig. S6).

3.2. Fabrication of gene delivery systems based on electrostatic self-assembly and physiochemical characterizations

The yielded functional block copolymer of RGD-PEG-PLys(thiol) was used to complex with polyanionic pDNA under gentle vortex, followed by 5 min incubation and sequential dialysis against DMSO-containing aqueous solution (DMSO: 10 mM) and distilled water for disulfide crosslinking. Note that the positively charged PLys segments could electrostatically assemble with the negatively charged plasmid DNA (pDNA) into polyionic complex core, and the non-ionic hydrophilic PEG segments would surround the formed PLys/pDNA complex core as the external shells (Fig. 2A). The resulting formation of RGD-PEG-PLys(thiol)/pDNA was characterized by DLS. As shown in Fig. 2B, nanoscaled formation possessing approximate 61.2 nm in hydrodynamic diameter was confirmed with unimodal size distribution (PDI: 0.09), which is contrast to the larger scale of naked pDNA (approximate 700 nm in hydrodynamic diameter by DLS measurement), suggesting the electrostatic condensation of pDNA by polycationic RGD-PEG-PLys(thiol) into favorable sub-100 nm nanoscale structures. Meanwhile, neutralization of the negative charges of pDNA (~38.4 mV) was also verified post complexation with RGD-PEG-PLys(thiol), as evidenced by the appreciable +2.4 mV for RGD-PEG-PLys(thiol)/pDNA. This appreciable neutral surface charge verified the excellent charge-masking function from PEG surface modification, which is critical in reducing electrostatic reactions in the complicated biological environment. Charge neutralization of pDNA was also confirmed by gel electrophoresis study for pDNA upon complexation with RGD-PEG-PLys(thiol)/pDNA at varied N/P ratios (defined as the molar ratio of the amine groups from block polymer to the phosphate groups from pDNA). As shown in Fig. S7, complete complexation of pDNA was identified at N/P ratios exceeding stochiometric charge ratio (N/P ≥ 1). Furthermore, the morphologies of pDNA condensates were characterized by TEM measurement. As shown in Fig. 2C, distinctive nanoscaled rod-like structures were observed, whose average length was measured to be approximate 100 nm. This distinctive rod-shape condensate is not surprising with respect that double-strand DNA (dsDNA) is rigid macromolecule, whose persistence length is approximate 50 nm in physiological condition. Consequently, the condensation of pDNA would follow a regular folding.
colloidal stabilities in the extracellular milieu, the proposed RGD-PEG-PLys(thiol)/pDNA self-assemblies is also designed to be capable of readily liberating the pDNA payloads in the cell interiors so as to facilitate the subsequent transcription and translation machinery. Given that the cell interior is characterized to be a significantly reducing compartment that commits to elimination of the detrimental reactive oxygen species, for instance, abundant reducing substances of glutathione (GSH) have documented in the cytosol (in the range of several 10–100 mM), yet the extracellular level of GSH was estimated to be in the range of serval 10–100 μM [27,28]. Therefore, the redox-responsive disulfide linkage in the constructed nanocolloids is envisioned to be selectively cleavable in the cytosol, while the disulfide crosslinking is fairly stable in extracellular milieu (including extracellular matrix and bloodstream). Consequently, the electrostatically-assembled nanocolloids lack of chemical crosslinking are susceptible to exchange reactions with polyanionic species in view of diverse anionic polyanions existing in the intracellular compartment (e.g. nucleic acids) and on the cytoplasm structures (e.g. glycosaminoglycans), leadingly facilitating pDNA release for subsequent DNA transcription and translation machinery. In consistent with our speculation, readily pDNA release was confirmed for RGD-PEG-PLys(thiol)/pDNA self-assemblies in presence of GSH (50 mM, mimicking the intracellular milieu), comparable to PEG-PLys/pDNA. To this end, the facile redox-responsive stabilities were confirmed for the proposed RGD-PEG-PLys(thiol)/pDNA self-assemblies, which afford adequate colloidal stabilities in the extracellular environment but readily dissociation and release of pDNA payloads in the targeted cell interiors, thereby beneficial in accomplishing promoted gene expression in the targeted cells.

3.4. Promoted cellular uptake and transfection due to disulfide crosslinking and surface RGD modification

Herein, the cellular uptake and gene expression efficacies were evaluated in HUVECs. Note that HUVECs are angiogenic endothelial cells that widely used as the model cells representative for vascular endothelial cells. To start up, the cellular uptake efficiencies of a class of polyplex micelles, including PEG-PLys/pDNA, PEG-PLys(thiol)/pDNA and RGD-PEG-PLys(thiol)/pDNA, were evaluated in HUVECs by flow cytometry and CLSM measurements (Fig. 4A). Overall, cell uptake appeared for all the polyplex micelles, implying the importance of fabrication of nanoscaled DNA condensates in pursuit of cell internalization. In details, limited cellular uptake efficiency was confirmed for PEG-PLys/pDNA (Fig. 4A). Especially, no additional cell uptake was observed for PEG-PLys/pDNA after 4 h transfection (Fig. 4A), which should be as a result of its poor colloidal stabilities in the biological milieu. Presumably, PEG-PLys/pDNA was susceptible to structural dissociation in the extracellular conditions, and structural disassembly occurred within the initial 4h incubation (Fig. 3). Namely, minimal nanoscaled self-assemblies remain after 4h incubation, therefore very limited cellular uptake efficiency could be expected despite extended incubation. On the contrary, consistent cellular uptake was observed for PEG-PLys(thiol)/pDNA, suggesting...
consistent gene expression was observed, and no significant decline was confirmed despite extended incubation. This long-term gene expression profile is apparently favorable to the ultimate therapeutic outcomes, namely the therapeutic proteins from our proposed gene therapeutic strategy were believed to conduce to potent and enduring anti-angiogenic microenvironment to suppress the pathogenesis.

3.5. Remarkable in vivo expression of anti-angiogenic proteins and potent suppression on CNV

With the aim of suppressing CNV, an anti-VEGF gene (plasmid DNA) encoding soluble fms-related tyrosine kinase 1 (sFlt-1), was attempted as the genomic payloads for construction of gene delivery systems. In view that VEGF plays a fundamental role in promoting neovascularization and edema in wAMD, disruption of VEGF signaling should serve as a rational approach to interfere the progression of CNV. Herein, CNV were induced according to our previously established laser photocoagulation protocol. At 24 h post photocoagulation, CNV was confirmed by fluorescence angiography. To explore the therapeutic efficacy of our constructed anti-VEGF gene delivery systems, varied dosages of RGD-PEG-PLys(thiol)-based self-assemblies containing anti-VEGF pDNA (sFlt-1) was administered via intravitreous injection. The expression levels of the therapeutic payloads of sFlt-1 pDNA were evaluated in CNV regions by ELISA at 48 h post dosage. As shown in Fig. 6A, markedly sFlt-1 expression was confirmed from our proposed gene delivery systems from RGD-PEG-PLys(thiol), which is envisioned to endow anti-VEGF microenvironment in suppressing angiogenesis. Herein, the therapeutic efficacy was assessed by fluorescence angiography on Day 7 post treatment. As shown in Fig. 6B, aggressive neovasculature was observed for the control PBS group. On the contrary, the commercial VEGF antibody of Conbercept appeared to exert potent inhibition on progression of neovascularization, as evidenced by reduced angiogenic blood vessels. Noteworthy is the efficacy of our proposed gene delivery systems containing sFlt-1, which exhibited significant suppression in the growth of neovasculature (Fig. 6B). Close examination identified the suppression activities followed distinct dosage-dependent
Fig. 6 – Therapeutic assessment on our proposed anti-angiogenic therapeutics composed of RGD-PEG-PLys(thiol). (A) Quantification of the expressed sFlt-1 by ELISA. (B) Insight into the CNV leakage by ocular fluorescence angiography on Day 7 post treatment of synthetic gene delivery system from RGD-PEG-PLys(thiol) (<1x > assigned to be 0.1 μg sFlt-1 pDNA). Note that intraperitoneal administration of fluorescein sodium was schemed prior to observation, scale bar: 200 μm.

manner, and significant eradication of neovasculature was achieved at dosage of 0.8 μg sFlt-1 pDNA. Furthermore, aiming for quantitatively estimation of the therapeutic efficacies, the vascular densities of the CNV lesions were quantified by calculating the positive areas of choroidal blood vessels post choroidal flatmount and immunostaining. Significant lowered CNV areas were confirmed for the sample of RGD-PEG-PLys(thiol)/sFlt-1 (Fig. 7). It should be noted that, there was no significant difference between the PBS control group RGD-PEG-PLys(thiol)/Luc (containing non-therapeutic Luc gene), suggesting the obtained therapeutic efficacies as a result of expression of the loaded anti-angiogenic sFlt-1. Presumably, RGD-PEG-PLys(thiol)/sFlt-1 due to its specific affinity to the angiogenic endothelial cells, could preferentially accumulate in the blood vessels. Furthermore, the proposed redox-responsive motif of the proposed RGD-PEG-PLys(thiol)/sFlt-1 self-assembly allowed efficient gene expression in the targeted endothelial cells. The expressed sFlt-1, once secreted from the cells, manage to diffuse around and readily trap the angiogenic VEGF cytokines, ultimately contributing to inhibited neovascularature. Noteworthy is the therapeutic efficacy of our proposed gene delivery systems based on single dosage comparable to the most potent antibody-based therapeutics (Conbercept), validating its clinical potential in treatment of wAMD. Hence, the prosperous potential of anti-angiogenic strategy in treatment of wAMD was verified based on intravitreal injection of gene delivery systems encapsulating sFlt-1 gene. Aside from the therapeutic efficacy, appreciable safety profile was also confirmed for our constructed gene delivery systems, as evidenced by their excellent biocompatibilities. As shown in Fig. S8, negligible cytotoxicity was confirmed for the self-assemblies of RGD-PEG-PLys(thiol)/pDNA, meanwhile, minimal hemolysis was also verified when RGD-PEG-PLys(thiol)/pDNA was incubated with defibrinated sheep red blood cells. At 6 h post incubation, the hemolysis rates of RBCs were verified to be rather negligible (merely 2% even at a high concentration up to 0.2 mg/ml, Fig. S9), in stark contrast to the hemolysis rates of RBCs under incubation with amphiphiles of Tween80 to be 20.1% and 72.8% at the concentration of 0.25 and 1 mg/ml). Together with appreciable therapeutic efficacies, our proposed anti-angiogenic gene delivery system of RGD-
PEG-Plys(thiol)/pDNA illustrates an intriguing tool for clinical persistent inhibition of CNV.

4. Conclusions

The rising population suffering from CNV encouraged tremendous efforts in development of potent therapeutics to tackle with this global leading cause for irreversible blindness. To manage this formidable disease, we are motivated to construct anti-angiogenic genomic therapeutics to verify the feasibility of gene therapy in treatment of CNV. In the present study, synthetic gene delivery system was rationally tailored with multifunctional motifs, including active targeting function to the angiogenic endothelial cells, stimuli-responsive stabilities to release the DNA payloads selectively in the cell interiors, which consequently contributed to efficient gene expression at the targeted cells. Note that the constructed delivery system encapsulating anti-angiogenic gene was determined to accomplish potent CNV suppression. Therefore, our proposed gene delivery system implied tremendous potential of gene therapy as an alternative approach for treatment of CNV. Considering the versatile genomic tools available in gene therapy, for instance, Crisp/Cas gene editing or RNA interference, our proposed gene delivery system could be further exploited to find broad utilities in achieving appropriate therapeutic consequences in treatment of intractable ocular diseases.

Conflicts of interest

The authors declare no competing financial interest.

Acknowledgments

This research was funded by National Natural Science Foundation of China (81900869, 81730026, 81802482), National Key R&D Program (2019YFC0840607, 2017YFA0105301), Science and Technology Commission of Shanghai Municipality (17411953000, 19495800700), Shanghai Sailing Program (19YF1439500), Talent Project of Revitalizing Liaoning (XLYC1807184), and Dalian Science&Technology Innovation Fund (2020JJ26SN050).

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.apjps.2021.04.001.

REFERENCES

[1] Xu D, Dávila JP, Rahimi M, Rehburn CB, Sarraf D. Long-term progression of type 1 neovascularization in age-related macular degeneration using optical coherence tomography angiography. Am J Ophthalmol 2018;187:10–20.
[2] Yan Z, Shi H, Zhu R, Li L, Guan H. Inhibition of YAP ameliorates choroidal neovascularization via inhibiting endothelial cell proliferation. Mol Vis 2018;24:83–93.
[3] Schecht S, Hariprasad SM, Movahedan A, Skondra D. Use of optical coherence tomography angiography in masqueraders of wet age-related macular degeneration and choroidal neovascularization. Ophthalmic Surg Lasers Imaging Retina 2018;49(2):80–5.
[4] Ammar MJ, Hsu J, Chiang A, Ho AC, Regillo CD. Age-related macular degeneration therapy: a review. Curr Opin Ophthalmol 2020;31(3):215–21.
[5] Hanus J, Zhao F, Wang S. Current therapeutic development for atrophic age-related macular degeneration. Br J Ophthalmol 2015;100(1):122–7.
[6] Cao J, Zhao L, Li Y, Liu Y, Xiao W, Song Y, et al. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap. Invest Ophthalmol Vis Sci 2010;51(11):609–17.
[7] Constable IJ, Pierce CM, Lai CM, Magno AL, Degli-Esposti MA, French MA, et al. Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration. EBioMedicine 2016;14:168–75.
[8] Huang H, Rachel P, Shen JK, Lutty GA, Vinores SA, Boulton ME. VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV. PLoS ONE 2013;8(8):e71808.
[9] Hutton-Smith LA, Gaffney EA, Byrne HM, Caruso A, Mazer NA. Theoretical insights into the retinal dynamics of vegf in patients treated with ranibizumab, based on an ocular pharmacokinetic/pharmacodynamic Model. Mol Pharm 2018;15:2770–84.
[10] Maier MM, Feucht N, Haas K, Fiore B, Lohmann CP. Intravitreal injection of bevacizumab for exudative AMD with occult or minimal classic choroidal neovascularisation (CNV). Klin Monbl Augenheilkd 2008;225(9):818–24.
[11] Michaelsson SR, Mikkel S, Henriette P, Jensen KE, Wiktor M, Helle B, et al. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance. Neuro-Oncology 2018;20(11):1462–74.
[12] Aslankurt M, Aslan I, Aksoy A, Erden B, Çekiç O. The results of switching between 2 Anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration. Eur J Ophthalmol 2013;23(4):553–7.
[13] Ehiken C, Jungmann S, Bohringer D, Agostini HT, Junker B, Pielen A. Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye 2014;28(5):538–45.
[14] Sun X, Yang S, Zhao J. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Dev Ther 2016;10:1857–67.
[15] Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432–44.
[16] Aya I, Makoto O, Takehiko I, Nobuhiro N, Kazunori K, Yasuhiro T, et al. Gene transfer using micellar nanovectors inhibits choroidal neovascularization in vivo. PLoS ONE 2011;6(12):e28560.
[17] Lai CM, Shen WY, Brankov M, Lai YK, Barnett NL, Lee SY, et al. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther 2005;12(4):659–68.
[18] Reid CA, Nettesheim ER, Connor TB, Lipinski DM. Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD. Sci Rep 2018;8(1):11763.
[19] Endo T, Itaka K, Shiyoyma M, Uchida S, Kataoka K. Gene transfection to spheroid culture system on micropatterned culture plate by polyplex nanomicelle: a novel platform of
genetically-modified cell transplantation. Drug Deliv Transl Res 2012;2(5):398–405.

[20] Ma C, Zhang X, Du C, Zhao B, He C, Li C, et al. Water-soluble cationic polyphosphazenes grafted with cyclic polyamine and imidazole as an effective gene delivery vector. Bioconjugate Chem 2016;27(4):1005–12.

[21] Cabral H, Miyata K, Osada K, Kataoka K. Block copolymer micelles in nanomedicine applications. Chem Rev 2018;118(14):6844–92.

[22] Alharbi NK, Spencer AJ, Salman AM, Tully CM, Chinnakannan SK, Lambe T, et al. Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. Vaccine 2016;34(1):49–55.

[23] Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999;286(5448):2244–5.

[24] Osada K, Oshima H, Kobayashi D, Doi M, Enoki M, Yamasaki Y, et al. Quantized folding of plasmid DNA condensed with block cationomer into characteristic rod structures promoting transgene efficacy. J Am Chem Soc 2010;132(35):12343–8.

[25] Tockary TA, Osada K, Motoda Y, Hiki S, Chen Q, Takeda KM, et al. Rod-to-globule transition of pDNA/PEG-Poly(L-lysine) polyplex micelles induced by a collapsed balance between DNA rigidity and PEG crowdedness. Small 2016;12(9):1193–200.

[26] Takeda KM, Osada K, Tockary TA, Dirisala A, Chen Q, Kataoka K. Poly(ethylene glycol) crowding as critical factor to determine pDNA packaging scheme into polypplex micelles for enhanced gene expression. Biomacromolecules 2017;18(1):36–43.

[27] Russo A, Degraff W, Friedman N, Mitchell JB. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res 1986;46(6):2845–8.

[28] Qu Y, Chu B, Wei X, Lei M, Hu D, Zha R, et al. Redox/pH dual-stimuli responsive camptothecin prodrug nanogels for “on-demand” drug delivery. J Control Release 2019;296:93–106.